Eltropag Tablet belongs to the class of 'platelet-stimulating agents' primarily used to treat low blood platelet count in patients with idiopathic thrombocytopenic purpura (ITP) and hepatitis C virus (HCV) infections. Eltropag Tablet is also used to treat severe aplastic anaemia (SAA) in adults. Idiopathic thrombocytopenic purpura is an immune condition associated with low levels of platelets. Hepatitis C is an infection and inflammation of the liver caused due to hepatitis C virus. Severe aplastic anaemia is a condition in which the bone marrow doesn't make enough blood cells.

Eltropag Tablet contains 'Eltrombopag' which belongs to the class of 'thrombopoietin receptor agonists'. Thrombopoietin is a glycoprotein hormone that stimulates the formation of megakaryocytes (large bone marrow cells) and further regulates platelet's production. Eltropag Tablet works by increasing these large bone marrow cells responsible for the production of platelets. Thus, Eltropag Tablet helps increase these bone marrow cells, thereby stimulating the number of platelets, which further lowers the risk of bleeding.

Take Eltropag Tablet as prescribed by your doctor. In some cases, Eltropag Tablet can cause common side effects like nausea, diarrhoea, headache, muscle pain, tiredness, loss of appetite, fever, anaemia (lack of blood cells), cough and tingling numbness. These side effects are not familiar to everyone who take Eltropag Tablet and vary individually. If you notice any side effects that are not manageable, please consult your doctor.

Let your doctor know if you have any allergic reactions to Eltropag Tablet or any other medicines, before starting Eltropag Tablet. It is essential to inform your doctor if you have any heart, kidney or liver problems, blood disorders, blood clotting problems and cataracts before starting Eltropag Tablet. It is advised to consult the doctor if you are pregnant or planning to conceive. Eltropag Tablet is not indicated for use in breastfeeding since it passes into the breast milk. Eltropag Tablet may make you dizzy, hence drive or operate machinery only when you are mentally alert. 

Eltropag Tablet contains 'Eltrombopag,' which belongs to the class of 'thrombopoietin receptor agonists' used to treat low blood platelet count in patients with immune (idiopathic) thrombocytopenic purpura (ITP), hepatitis C virus (HCV) infections and severe aplastic anaemia (SAA) in adults. Eltropag Tablet works by increasing megakaryocytes, the large bone marrow cells responsible for the production of platelets. The increase in these bone marrow cells stimulates the production of platelets. Thus Eltropag Tablet prevents bleeding episodes by increasing the number of platelets in the blood.

If you are known to be allergic to Eltropag Tablet or other medicines, please inform your doctor in advance. Brief your medical history if you have blood clots, clotting disorders (Factor V Leiden), blood disorders like blood cancer, myelodysplastic syndrome, cataracts, liver or kidney diseases before starting Eltropag Tablet. Take Eltropag Tablet at least two hours before or four hours after consuming antacids, mineral and vitamin supplements (iron, calcium, magnesium, aluminium, selenium and zinc), dairy products, calcium-enriched foods and fortified juices since they interfere with the absorption of Eltropag Tablet. Eltropag Tablet is not recommended during pregnancy since it may have harmful effects on the foetus. Consult your doctor before using Eltropag Tablet if you are a breastfeeding mother. Do not drive or operate machinery since Eltropag Tablet may cause side effects like dizziness and tiredness, affecting your ability to concentrate and drive. Avoid or limit alcohol consumption with Eltropag Tablet as it may affect the efficacy of Eltropag Tablet. Eltropag Tablet is not recommended for children less than one year of age in ITP and children less than two years of age in SAA. 

• Keep a check on your daily blood pressure and blood sugar levels and if you notice any fluctuations, please consult a doctor.
• Since Eltropag Tablet affects liver enzymes, your doctor may suggest liver function tests to check your aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin levels before starting treatment and every two weeks after the treatment with Eltropag Tablet.
• Eltropag Tablet may also interfere with creatinine and bilirubin lab tests, hence, please inform your doctor and laboratory staff in advance.